Zymeworks Q2 FY26 net loss widens to $45 million; revenue guidance rises

First-half 2026 GAAP net loss widened to $89.2 million from $20.3 million a year earlier. Updated 2026 outlook calls for revenue of $278 million to $292 million and adjusted EBITDA of $114 million to $128 million after the Theravance Biopharma acquisition.